Xuesong Guan

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

David C. Klonoff, John B. Buse, Loretta L. Nielsen et al. · Current Medical Research and Opinion · 2007 · 700 citations

Medicine, Endocrinology, Pharmacology +13

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

Ralph A. DeFronzo, Ted Okerson, Prabhakar Viswanathan et al. · Current Medical Research and Opinion · 2008 · 374 citations

Medicine, Endocrinology, Pharmacology +17

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

John B. Buse, David C. Klonoff, Loretta L. Nielsen et al. · Clinical Therapeutics · 2007 · 280 citations

Medicine, Endocrinology, Pharmacology +17

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

David C. Klonoff, John B. Buse, Loretta L. Nielsen et al. · Current Medical Research and Opinion · 2008 · 227 citations

Medicine, Endocrinology, Pharmacology +13

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht et al. · International Journal of Colorectal Disease · 2017 · 142 citations · Full text

Medicine, Oncology, Pharmacotherapy +11